Tomoki Imaoka
Overview
Explore the profile of Tomoki Imaoka including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
293
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Karibe T, Imaoka T, Abe K, Ando O
Drug Metab Dispos
. 2018 Jan;
46(5):667-679.
PMID: 29358184
To estimate the clinical impact of pharmacokinetic modulation via breast cancer resistance protein (BCRP), in vivo approaches in nonclinical settings are desired in drug development. Clinical observation has identified curcumin...
12.
Mikkaichi T, Nakai D, Yoshigae Y, Imaoka T, Okudaira N, Izumi T
Drug Metab Pharmacokinet
. 2015 Sep;
30(5):334-40.
PMID: 26403085
Organic anion transporting polypeptide (OATP) 1B1 and 1B3 are key molecules that are involved in hepatic uptake related to drug elimination, and OATP-mediated drug interactions are of clinical concern. In...
13.
Karibe T, Hagihara-Nakagomi R, Abe K, Imaoka T, Mikkaichi T, Yasuda S, et al.
Pharm Res
. 2014 Nov;
32(5):1634-47.
PMID: 25380981
Purpose: To evaluate whether the impact of functional modulation of the breast cancer resistance protein (BCRP, ABCG2 421C>A) on human pharmacokinetics after oral administration is predictable using Bcrp knockout mice...
14.
Mikkaichi T, Yoshigae Y, Masumoto H, Imaoka T, Rozehnal V, Fischer T, et al.
Drug Metab Dispos
. 2014 Jan;
42(4):520-8.
PMID: 24459178
Edoxaban (the free base of DU-176b), an oral direct factor Xa inhibitor, is mainly excreted unchanged into urine and feces. Because active membrane transport processes such as active renal secretion,...
15.
Imaoka T, Mikkaichi T, Abe K, Hirouchi M, Okudaira N, Izumi T
Drug Metab Dispos
. 2013 May;
41(7):1442-9.
PMID: 23640987
Cumulative studies describe the importance of drug transporters as one of the key determinants of pharmacokinetics that necessitate investigation and assessment of the involvement of drug transporters in drug discovery...
16.
Imaoka T, Kusuhara H, Adachi M, Schuetz J, Takeuchi K, Sugiyama Y
Mol Pharmacol
. 2006 Nov;
71(2):619-27.
PMID: 17110501
Acyclic nucleotide phosphonates (adefovir, cidofovir, and tenofovir) are eliminated predominantly into the urine, and renal failure is their dose-limiting toxicity, particularly for adefovir and cidofovir. In this study, we examined...
17.
Tahara H, Kusuhara H, Endou H, Koepsell H, Imaoka T, Fuse E, et al.
J Pharmacol Exp Ther
. 2005 Jul;
315(1):337-45.
PMID: 16006492
A clinical drug-drug interaction between famotidine (a H2 receptor antagonist) and probenecid has not been reproduced in rats. The present study hypothesized that the species-dependent probenecid sensitivity is due to...
18.
Nagata Y, Kusuhara H, Imaoka T, Endou H, Sugiyama Y
J Pharm Sci
. 2004 Sep;
93(11):2724-32.
PMID: 15389674
2,4-Dichlorophenoxyacetic acid (2,4-D) is an anionic herbicide. The purpose of the present study is to examine whether organic anion transporter 3 (Oat3; Slc22a8) is solely responsible for the uptake of...
19.
Imaoka T, Kusuhara H, Adachi-Akahane S, Hasegawa M, Morita N, Endou H, et al.
J Am Soc Nephrol
. 2004 Jul;
15(8):2012-22.
PMID: 15284287
The renal secretion of organic anions across the proximal tubules is achieved by a coordination of uptake and efflux transporters. This study reports the expression, localization, and functional properties of...